Radius Health, Inc. (RDUS) in Waltham, Mass., is a biopharmaceutical company that is focused on addressing unmet medical needs in bone health, orphan diseases, and oncology. Its lead product, TYMLOS, is an abaloparatide injection to treat postmenopausal women with osteoporosis at high risk for fracture.
The COVID-19 pandemic has highlighted the limitations of global healthcare. Biotechnology stocks have garnered significant investor interest since the onset of the public health crisis due to these companies’ role in developing treatments and vaccines to fight the virus. Furthermore, scientific breakthroughs in biotechnology have enabled new ways of treating and preventing diseases. And according to a Precedence Research report, the biotechnology market is expected to reach $1.68 trillion by 2030, growing at a 8.7% CAGR. Given RDUS’ strong fundamentals, we think it is well-positioned to capitalize on the industry’s solid growth prospects.
